EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan’s Ministry of Health, ...
DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced ...
New Australian research has highlighted the urgent need for a national framework to guide genetic testing for prostate cancer, with experts warning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results